EN | SE Contact us

Scientific Publications

Vargas FA, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C, Henry JY, Spain L, Aissa AB, Georgiou A, Wong YNS, Smith M, Strauss D, Hayes A, Nicol D, O’Brien T, Mårtensson L, Ljungars A, Teige I, Frendéus B, TRACERx Melanoma, TRACERx Renal and TRACERx Lung consortia, Pule M, Marafioti T, Gore M, Larkin J, Turajlic S, Swanton C, Peggs KS, Quezada SA. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies Cancer Cell. 2018, April 9, 33(4):649-663

Roghanian A, Teige I, Mårtensson L, Cox K, Kovacek M, Ljungars A, Mattsson J,Sundberg A, Vaughan AT, Shah V, Smyth NR, Sheth B, Chan CHT, Li ZL, Williams E, Manfredi G,Oldham RJ, Mockridge IC,James SA, Dahal LN, Hussain K,Nilsson B,Verbeek SJ, Juliusson G, Hansson M, Jerkeman M,Johnson PWM,Davies A, Beers SA,Glennie MJ,Frendéus B, Cragg MS. Antagonistic Human FcgRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo. Cancer Cell. 2015, April 13, 27:473–488

Hansson M, Gimsing P, Badros AZ, Martinsson-Niskanen T, Nahi H, Offner F, Salomo M, Sonesson E, Mau-Sorensen M, Stenberg Y, Sundberg A, Teige I, van Droogenbroeck J, Wichert S, Zangari M, Frendeus B, Korsgren M, Poelman M and Tricot G. A phase 1 dose-escalation study of antibody BI-505 in relapsed/refractory multiple myeloma. Clinical Cancer Research. 2015 Febr 24, 2015 10.1158/1078-0432.CCR-14-1661

Hussain K, Hargreaves CE, Roghanian A, Oldham RJ, Chan HT, Mockridge CI, Chowdhury F, Frendéus B, Harper KS, Strefford JC, Cragg MS, Glennie MJ, Williams AP, French RR. Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412. Blood. 2015 Jan 1;125(1):102-10

Lehrer-Graiwer J, Singh P, Abdelbaky A, Vucic E, Korsgren M, Baruch A, Fredrickson J, van Bruggen N, Tang MT, Frendeus B, Rudd JH, Hsieh F, Ballantyne CM, Ghoshhajra B, Rosenson RS, Koren M, Roth EM, Duprez DA, Fayad ZA, Tawakol AA. A Phase II Study of the Safety, Tolerability, and Anti-Inflammatory Activity as Assessed by FDG-PET of MLDL1278A, a Monoclonal Antibody Against Oxidized LDL, in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease. JACC Cardiovasc Imaging. 2014 Nov 12. pii: S1936-878X(14)00780-3

Vaughan AT, Iriyama C, Beers SA, Chan CH, Lim SH, Williams EL, Shah V, Roghanian A, Frendéus B, Glennie MJ, Cragg MS. Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. Blood. 2014 Jan 30;123(5):669-77

Li S, Kievit P, Robertson AK, Kolumam G, Li X, von Wachenfeldt K, Valfridsson C, Bullens S, Messaoudi I, Bader L, Cowan KJ, Kamath A, van Bruggen N, Bunting S, Frendéus B, Grove KL. Targeting oxidized LDL improves insulin sensitivity and immune cell function in obese Rhesus macaques. Mol Metab. 2013 Jun 11;2(3):256-69

Frendéus B. Function-first antibody discovery: Embracing the unpredictable biology of antibodies. Oncoimmunology. 2013 Aug 1;2(8):e25047. Epub. 2013 May 20

Veitonmäki N, Hansson M, Zhan F, Sundberg A, Löfstedt T, Ljungars A, Li Z, Martinsson-Niskanen T, Zeng M, Yang Y, Danielsson L, Kovacek M, Lundqvist A, Mårtensson L, Teige I, Tricot G, Frendéus B. A Human ICAM-1 Antibody Isolated by a Function-First Approach Has Potent Macrophage-Dependent Antimyeloma Activity In Vivo. Cancer Cell. 2013 Apr 15;23(4):502-15

Verhamme P, Pakola S, Jensen TJ, Berggren K, Sonesson E, Saint-Remy JM, Balchen T, Belmans A, Cahillane G, Stassen JM, Peerlinck K, Glazer S, Jacquemin M. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers. Clin Ther. 2010 Jun;32(6):1205-20.

Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, Autiero M, Wyns S, Plaisance S, Moons L, van Rooijen N, Giacca M, Stassen JM, Dewerchin M, Collen D, Carmeliet P. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007;131(3):463-75.

Ström A, Fredrikson GN, Schiopu A, Ljungcrantz I, Söderberg I, Jansson B, Carlsson R, Hultgårdh-Nilsson A, Nilsson J. Inhibition of injury-induced arterial remodelling and carotid atherosclerosis by recombinant human antibodies against aldehyde-modified apoB-100. Atherosclerosis. 2007;190(2):298-305.

Schiopu A, Frendéus B, Jansson B, Söderberg I, Ljungcrantz I, Araya Z, Shah PK, Carlsson R, Nilsson J, Fredrikson GN. Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice. J Am Coll Cardiol. 2007;50(24):2313-8. 

Fransson J, Tornberg UC, Borrebaeck CA, Carlsson R, Frendéus B. Rapid induction of apoptosis in B-cell lymphoma by functionally isolated human antibodies. Int J Cancer. 2006;119(2):349-58. 

Schiopu A, Bengtsson J, Söderberg I, Janciauskiene S, Lindgren S, Ares MP, Shah PK, Carlsson R, Nilsson J, Fredrikson GN. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation. 2004;110(14):2047-52.

Söderlind E, Strandberg L, Jirholt P, Kobayashi N, Alexeiva V, Aberg AM, Nilsson A, Jansson B, Ohlin M, Wingren C, Danielsson L, Carlsson R, Borrebaeck CA. Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries. Nat Biotechnol. 2000;18(8):852-6.